Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib

Blood Cancer Journal

Volumn 2, Issue 4, 2012, Pages

  Ishii, T ^a   Seike, T ^a   Nakashima, T ^a   Juliger, S ^b   Maharaj, L ^b   Soga, S ^a   Akinaga, S ^a   Cavenagh, J ^b   Joel, S ^b   Shiotsu, Y ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Apoptosis; Heat shock protein 90; Proteasome

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CASPASE 2; CASPASE 3; CASPASE 9; GLUCOSE REGULATED PROTEIN 78; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90 INHIBITOR; KW 2478; PROTEIN NOXA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PROTEIN EXPRESSION;

EID: 84864038902     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2012.13     Document Type: Article

References (27)

1. Lonial S, Cavenagh J. Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma. Br J Haematol 2009; 145: 681-708.
2. Kastritis E, Zervas K, Symeonidis A, Terpos E, Delimbassi S, Anagnostopoulos N et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia 2009; 23: 1152-1157.
3. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520.
4. Chanan-Khan AA, Borrello I, Lee KP, Reece DE. Development of target-specific treatments in multiple myeloma. Br J Haematol 2010; 151: 3-15.
5. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clinical Oncology 2005; 23: 630-639.
6. Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 2007; 67: 1783-1792.
7. Allegra A, Sant'antonio E, Penna G, Alonci A, D'Angelo A, Russo S et al. Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors. Eur J Haematol 2011; 86: 93-110.
8. Davenport EL, Moore HE, Dunlop AS, Sharp SY, Workman P, Morgan GJ et al. Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood 2007; 110: 2641-2649.
9. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Kung AL, Davies FE et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 2006; 107: 1092-1100.
10. Duus J, Bahar HI, Venkataraman G, Ozpuyan F, Izban KF, Al-Masri H et al. Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma. Leuk Lymphoma 2006; 47: 1369-1378.
11. Sydor JR, Normant E, Pien CS, Porter JR, Ge J, Grenier L et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci USA. 2006; 103: 17408-17413.
12. Wright JJ. Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clin Cancer Res 2010; 16: 4094-4104.
13. Richardson PG, Badros AZ, Jagannath S, Tarantolo S, Wolf JL, Albitar M et al. Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. Br J Haematol 2010; 150: 428-437.
14. Nakashima T, Ishii T, Tagaya H, Seike T, Nakagawa H, Kanda Y et al. New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells. Clin Cancer Res 2010; 16: 2792-2802.
15. Katagiri S, Yonezawa T, Kuyama J, Kanayama Y, Nishida K, Abe T et al. Two distinct human myeloma cell lines originating from one patient with myeloma. Int J Cancer 1985; 36: 241-246.
16. Gazdar AF, Oie HK, Kirsch IR, Hollis GF. Establishment and characterization of a human plasma cell myeloma culture having a rearranged cellular myc protooncogene. Blood 1986; 67: 1542-1549.
17. Nakashima T, Tanaka R, Yamashita Y, Kanda Y, Hara M. Aranorosin and a novel derivative inhibit the anti-apoptotic functions regulated by Bcl-2. Biochem Biophys Res Commun 2008; 377: 1085-1090.
18. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
19. Schmidmaier R, Baumann P, Meinhardt G. Cell-cell contact mediated signalling -no fear of contact. Exp Oncol 2006; 28: 12-15.
20. Webb JL (ed.). Effect of more than one inhibitor, antagonism, summation, and synergism. Enzyme Metabolic Inhibitor, Vol 1. Academic Press: New York, 1963, pp 488-512.
21. Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V et al. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 2005; 65: 6282-6293.
22. Gomez-Bougie P, Wuillème-Toumi S, Ménoret E, Trichet V, Robillard N, Philippe M et al. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res 2007; 67: 5418-5424.
23. Wang Q, Mora-Jensen H, Weniger MA, Perez-Galan P, Wolford C, Hai T et al. ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. Proc Natl Acad Sci USA 2009; 106: 2200-2205.
24. Noonan EJ, Place RF, Giardina C, Hightower LE. Hsp70B' regulation and function. Cell stress Chaperones 2007; 12: 393-402.
25. Hongtao Gu Xiequn, Chen Guangxun, Gao Hongjuan Dong. Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells. Mol Cancer Ther 2008; 7: 2298-2307.
26. Roué G, Pérez-Galán P, Mozos A, López-Guerra M, Xargay-Torrent S, Rosich L et al. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78. Blood 2011; 117: 1270-1279.
27. Neznanov N, Komarov AP, Neznanova L, Stanhope-Baker P, Gudkov AV. Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib. Oncotarget 2011; 2: 209-221.